Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARVN 
Arvinas Inc (ARVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $18.44
1 Year Target Price $18.44
| 9 | Strong Buy |
| 4 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.8% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 569.72M USD | Price to earnings Ratio - | 1Y Target Price 18.44 |
Price to earnings Ratio - | 1Y Target Price 18.44 | ||
Volume (30-day avg) 21 | Beta 2.23 | 52 Weeks Range 5.90 - 29.61 | Updated Date 08/28/2025 |
52 Weeks Range 5.90 - 29.61 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.47% | Operating Margin (TTM) -314.73% |
Management Effectiveness
Return on Assets (TTM) -6.71% | Return on Equity (TTM) -12.01% |
Valuation
Trailing PE - | Forward PE 17.7 | Enterprise Value -281579463 | Price to Sales(TTM) 1.53 |
Enterprise Value -281579463 | Price to Sales(TTM) 1.53 | ||
Enterprise Value to Revenue 5.69 | Enterprise Value to EBITDA -1.62 | Shares Outstanding 73417600 | Shares Floating 62205994 |
Shares Outstanding 73417600 | Shares Floating 62205994 | ||
Percent Insiders 6.85 | Percent Institutions 94.19 |
Upturn AI SWOT
Arvinas Inc
Company Overview
History and Background
Arvinas Inc. was founded in 2013 and is a biopharmaceutical company focused on developing protein degradation therapeutics. They pioneered the development of PROTACs (proteolysis-targeting chimeras) for drug discovery. They have evolved from a research-focused startup to a clinical-stage company with multiple programs in development.
Core Business Areas
- Protein Degradation Therapeutics: Arvinas focuses on developing therapies based on its PROTAC platform. These therapies are designed to degrade disease-causing proteins, offering a novel approach to drug development.
- Oncology: A major focus is on developing PROTAC degraders for cancer treatment, targeting key proteins involved in tumor growth and survival.
- Neuroscience: They are expanding into neuroscience, aiming to develop PROTAC degraders for neurological disorders.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and biotechnology. The organizational structure is typical of a biopharmaceutical company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Bavdegalutamide (ARV-110): An oral PROTAC degrader of the androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 3 clinical trials. Market share is currently 0% but could capture a portion of the mCRPC market (estimated at multi-billion USD). Competitors include companies with existing AR inhibitors such as Pfizer (ENZALUTAMIDE), Johnson & Johnson (APALUTAMIDE), and others developing next-generation therapies.
- ARV-766: A novel PROTAC AR degrader designed for enhanced AR degradation. Currently in clinical trials. Market share is currently 0% but aims to compete with ARV-110 and other AR inhibitors in the prostate cancer space. Competitors are similar to ARV-110.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. There's a growing interest in targeted protein degradation as a therapeutic approach.
Positioning
Arvinas is a leader in the PROTAC field, with a strong patent portfolio and a first-mover advantage. They are positioned to potentially disrupt traditional drug development.
Total Addressable Market (TAM)
The total addressable market is very broad and varies by the indication being targeted, such as Prostate cancer and other AR related indications. Prostate cancer alone is a multi-billion dollar market. Arvinas is positioned well to potentially capture a large share of these markets if clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Pioneering PROTAC technology
- Strong patent portfolio
- Experienced leadership team
- Multiple clinical-stage programs
- Strategic partnerships
Weaknesses
- High research and development costs
- Clinical trial risks
- Reliance on PROTAC technology
- Relatively small company size
Opportunities
- Expanding PROTAC applications to new diseases
- Partnering with larger pharmaceutical companies
- Advancing clinical programs to commercialization
- Developing next-generation PROTACs
Threats
- Competition from other protein degradation technologies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property challenges
- Financing risks
Competitors and Market Share
Key Competitors
- KYMR
- MRTX
- MDGL
- VRTX
Competitive Landscape
Arvinas is competing in the broader pharmaceutical and biotech space. The competitive landscape is evolving, with emerging companies also developing protein degradation technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by increasing R&D investment and expansion of the clinical pipeline.
Future Projections: Future growth is dependent on the success of clinical trials and potential commercialization of PROTAC therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing Bavdegalutamide (ARV-110) into Phase 3 trials, expanding the pipeline with new PROTAC candidates, and forging strategic partnerships.
Summary
Arvinas Inc. is a pioneering biopharmaceutical company in the field of targeted protein degradation using PROTAC technology. Their lead product candidate, ARV-110, is in Phase 3 clinical trials for prostate cancer, representing a significant potential growth driver. The company's financial health depends on partnerships, collaborations, and successful clinical outcomes. Potential risks include clinical trial failures, competition, and regulatory hurdles, which highlight that its overall success is dependent on successful trial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arvinas Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Research
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arvinas Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-09-27 | Chairperson, CEO & President Dr. John G. Houston Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 430 | Website https://www.arvinas.com |
Full time employees 430 | Website https://www.arvinas.com | ||
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.